The impact of pre-transplant donor specific antibodies on the outcome of kidney transplantation - Data from the Swiss transplant cohort study.
abmr
donor specific antibodies
graft loss
kidney transplantation
virtual cross-match
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
07
2022
accepted:
05
09
2022
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
Pre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antigen (HLA) protein variants present in the donor organ, have been associated with worse outcomes in kidney transplantation. The impact of the mean fluorescence intensity (MFI) and the target HLA antigen of the detected DSA has, however, not been conclusively studied in a large cohort with a complete virtual cross-match (vXM). We investigated the effect of pre-transplant DSA on the risk of antibody-mediated rejection (ABMR), graft loss, and the rate of eGFR decline in 411 DSA positive transplants and 1804 DSA negative controls. Pre-transplant DSA were associated with a significantly increased risk of ABMR, graft loss, and accelerated eGFR decline. DSA directed at Class I and Class II HLA antigens were strongly associated with increased risk of ABMR, but only DSA directed at Class II associated with graft loss. DSA MFI markedly affected outcome, and Class II DSA were associated with ABMR already at 500-1000 MFI, whereas Class I DSA did not affect outcome at similar low MFI values. Furthermore, isolated DSA against HLA-DP carried comparable risks for ABMR, accelerated eGFR decline, and graft loss as DSA against HLA-DR. Our results have important implications for the construction and optimization of vXM algorithms used within organ allocation systems. Our data suggest that both the HLA antigen target of the detected DSA as well as the cumulative MFI should be considered and that different MFI cut-offs could be considered for Class I and Class II directed DSA.
Sections du résumé
Background
Pre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antigen (HLA) protein variants present in the donor organ, have been associated with worse outcomes in kidney transplantation. The impact of the mean fluorescence intensity (MFI) and the target HLA antigen of the detected DSA has, however, not been conclusively studied in a large cohort with a complete virtual cross-match (vXM).
Methods
We investigated the effect of pre-transplant DSA on the risk of antibody-mediated rejection (ABMR), graft loss, and the rate of eGFR decline in 411 DSA positive transplants and 1804 DSA negative controls.
Results
Pre-transplant DSA were associated with a significantly increased risk of ABMR, graft loss, and accelerated eGFR decline. DSA directed at Class I and Class II HLA antigens were strongly associated with increased risk of ABMR, but only DSA directed at Class II associated with graft loss. DSA MFI markedly affected outcome, and Class II DSA were associated with ABMR already at 500-1000 MFI, whereas Class I DSA did not affect outcome at similar low MFI values. Furthermore, isolated DSA against HLA-DP carried comparable risks for ABMR, accelerated eGFR decline, and graft loss as DSA against HLA-DR.
Conclusion
Our results have important implications for the construction and optimization of vXM algorithms used within organ allocation systems. Our data suggest that both the HLA antigen target of the detected DSA as well as the cumulative MFI should be considered and that different MFI cut-offs could be considered for Class I and Class II directed DSA.
Identifiants
pubmed: 36211367
doi: 10.3389/fimmu.2022.1005790
pmc: PMC9532952
doi:
Substances chimiques
Antibodies
0
HLA Antigens
0
HLA-DP Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1005790Investigateurs
Patrizia Amico
(P)
Andres Axel
(A)
John David Aubert
(JD)
Vanessa Banz
(V)
Beckmann Sonja
(B)
Guido Beldi
(G)
Christoph Berger
(C)
Ekaterine Berishvili
(E)
Isabelle Binet
(I)
Pierre-Yves Bochud
(PY)
Sanda Branca
(S)
Heiner Bucher
(H)
Thierry Carrel
(T)
Emmanuelle Catana
(E)
Yves Chalandon
(Y)
Sabina De Geest
(S)
Olivier De Rougemont
(O)
Michael Dickenmann
(M)
Joëlle Lynn Dreifuss
(JL)
Michel Duchosal
(M)
Thomas Fehr
(T)
Sylvie Ferrari-Lacraz
(S)
Nicola Franscini
(N)
Christian Garzoni
(C)
Paola Gasche Soccal
(PG)
Christophe Gaudet
(C)
Déla Golshayan
(D)
Nicolas Goossens
(N)
Karine Hadaya
(K)
Jörg Halter
(J)
Dominik Heim
(D)
Christoph Hess
(C)
Sven Hillinger
(S)
Hans Hirsch
(H)
Patricia Hirt
(P)
Günther Hofbauer
(G)
Uyen Huynh-Do
(U)
Franz Immer
(F)
Michael Koller Head Of The Data Center
(MKHOTD)
Mirjam Laager
(M)
Bettina Laesser
(B)
Roger Lehmann
(R)
Alexander Leichtle
(A)
Christian Lovis
(C)
Oriol Manuel
(O)
Hans-Peter Marti
(HP)
Pierre Yves Martin
(PY)
Michele Martinelli
(M)
Valérie McLin
(V)
Katell Mellac
(K)
Aurelia Mercay
(A)
Karin Mettler
(K)
Nicolas Mueller Chairman Scientific Committee
(NMCS)
Antonia Müller
(A)
Thomas Müller
(T)
Ulrike Müller-Arndt
(U)
Beat Müllhaupt
(B)
Mirjam Nägeli
(M)
Graziano Oldani
(G)
Manuel Pascual Executive Office
(MPE)
Klara Posfay-Barbe
(K)
Juliane Rick
(J)
Anne Rosselet
(A)
Simona Rossi
(S)
Silvia Rothlin
(S)
Frank Ruschitzka
(F)
Urs Schanz
(U)
Stefan Schaub
(S)
Aurelia Schnyder
(A)
Macé Schuurmans
(M)
Thierry Sengstag
(T)
Federico Simonetta
(F)
Katharina Staufer
(K)
Susanne Stampf
(S)
Jürg Steiger Head
(JS)
Excecutive Office
(E)
Guido Stirniman
(G)
Ueli Stürzinger
(U)
Christian Van Delden Executive Office
(CVDE)
Jean-Pierre Venetz
(JP)
Jean Villard
(J)
Julien Vionnet Madeleine Wick Stcs Coordinator
(JVMWS)
Markus Wilhlem
(M)
Patrick Yerly
(P)
Informations de copyright
Copyright © 2022 Frischknecht, Deng, Wehmeier, de Rougemont, Villard, Ferrari-Lacraz, Golshayan, Gannagé, Binet, Wirthmueller, Sidler, Schachtner, Schaub, Nilsson and the Swiss Transplant Cohort Study.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Am Soc Nephrol. 2019 Sep;30(9):1735-1745
pubmed: 31292197
Hum Immunol. 1992 Jan;33(1):5-9
pubmed: 1548149
Transpl Int. 1995;8(3):180-4
pubmed: 7626176
Am J Transplant. 2018 Feb;18(2):293-307
pubmed: 29243394
Am J Transplant. 2012 Feb;12(2):388-99
pubmed: 22081892
Transplantation. 2016 Jan;100(1):159-66
pubmed: 26262501
Kidney Int. 2012 Sep;82(5):598-604
pubmed: 22622504
Nephrol Dial Transplant. 2019 Jun 1;34(6):1056-1063
pubmed: 30365008
Lancet. 2017 May 27;389(10084):2152-2162
pubmed: 28561006
N Engl J Med. 2004 Dec 23;351(26):2761-6
pubmed: 15616214
Transplantation. 2018 Apr;102(4):557-568
pubmed: 29315141
Transpl Int. 2021 Dec;34(12):2755-2768
pubmed: 34561920
Transpl Int. 2011 Jun;24(6):560-9
pubmed: 21332582
Transplantation. 2013 May 15;95(9):1113-9
pubmed: 23514959
Am J Transplant. 2012 Oct;12(10):2845-8
pubmed: 22759079
Am J Transplant. 2018 Sep;18(9):2274-2284
pubmed: 29464832
Hum Immunol. 2012 Sep;73(9):879-83
pubmed: 22841893
Transplantation. 2021 Mar 1;105(3):648-659
pubmed: 33617203
J Am Soc Nephrol. 2019 Nov;30(11):2262-2274
pubmed: 31653784
N Engl J Med. 2018 Sep 20;379(12):1150-1160
pubmed: 30231232
Am J Transplant. 2017 Aug;17(8):2092-2102
pubmed: 28245084
Am J Transplant. 2011 Oct;11(10):2132-43
pubmed: 21812918
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Transplantation. 2006 Apr 15;81(7):953-65
pubmed: 16612264
Am J Transplant. 2015 Nov;15(11):2921-30
pubmed: 26096305
J Am Soc Nephrol. 2017 Jun;28(6):1912-1923
pubmed: 28255002
Transplantation. 2012 Oct 27;94(8):775-83
pubmed: 23032865
Transplantation. 2011 Mar 15;91(5):527-35
pubmed: 21192319
Transpl Int. 2019 Aug;32(8):775-788
pubmed: 30955215
Am J Transplant. 2019 Nov;19(11):3100-3113
pubmed: 31062492
J Am Soc Nephrol. 2010 Aug;21(8):1398-406
pubmed: 20634297